Clinical Trials Logo

Clinical Trial Summary

Caesarean delivery is inevitably associated with a higher amount of blood loss vis-à-vis primary postpartum haemorrhage, when compared to vaginal delivery. Oxytocin use in tropical developing countries for the reduction blood loss at caesarean section have been met with challenges of ineffectiveness due to poor transportation, inadequate storage and drug adulteration. Therefore, there is a need for an effective, temperature stable uterotonic with a lesser risk of adulteration. The study is aimed at evaluating the effectiveness and safety of adjunctive sublingual misoprostol in reducing intraoperative blood loss at caesarean section.


Clinical Trial Description

It would be a double blind randomized controlled trial. One hundred and fifty-two pregnant women at term who have indications for caesarean section and have risk factors for primary postpartum haemorrhage, as well as meet the eligibility criteria would be randomized equally into two study arms (Misoprostol study arm and Placebo study arm) after informed consent. The Misoprostol study arm will receive 400 mcg of sublingual misoprostol as two 200 mcg misoprostol tablets. The Placebo study arm would receive two sublingual placebo tablets similar to the misoprostol tablets. The Misoprostol and the Placebo tablets will be given in each study arm at the point of starting the uterine incision at caesarean section. Both study arms would receive routine intravenous oxytocin at the time of clamping of the umbilical cord. The outcome measures will be estimated intraoperative blood loss, the need for additional intraoperative oxytocic, blood transfusion, the occurrence of side effects, and incidence of primary postpartum haemorrhage. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05532215
Study type Interventional
Source Federal Medical Centre, Yenagoa
Contact Stanley E Ozori
Phone +2348065876000
Email ozoriniseod@yahoo.com
Status Recruiting
Phase N/A
Start date March 14, 2023
Completion date November 14, 2023

See also
  Status Clinical Trial Phase
Completed NCT03680339 - The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS Phase 4
Completed NCT03693599 - Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean Phase 4
Completed NCT03707132 - Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
Recruiting NCT02306733 - Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally Phase 3
Completed NCT01866241 - Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage Phase 3
Not yet recruiting NCT01236482 - Oxytocin in Cesarean Delivery Phase 4
Completed NCT03784794 - Patient Blood Management for Massive Obstetric Hemorrhage N/A
Recruiting NCT04401839 - Amr Maneuver for Prevention of Postpartum Hemorrhage N/A
Not yet recruiting NCT06219538 - DAISY Uterine Drain Device Evaluation N/A
Completed NCT01863706 - Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage Phase 1
Not yet recruiting NCT05488457 - Oxytocin Pharmacokinetics and Pharmacodynamics Phase 2
Terminated NCT04277962 - Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial N/A
Completed NCT04723979 - NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
Completed NCT03570723 - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa N/A
Completed NCT03117647 - Mansoura-VV Uterine Compression Suture for Primary Atonic Postpartum Hemorrhage N/A
Active, not recruiting NCT03069859 - Use of TXA to Prevent Postpartum Hemorrhage Phase 2
Not yet recruiting NCT03891082 - A Comparative Study Between Bakri Balloon and B Lynch Suture Used to Control Primary Postpartum Hemorrhage After Cesarean Section N/A
Not yet recruiting NCT03463070 - Misoprostol Before and After Cesarean Section Phase 3
Not yet recruiting NCT06255496 - QStat Cartridge in Obstetric Patients
Completed NCT03907605 - Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Ligation for Postpartum Hemorrage (PPH)